

## Zambia support for Measles vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Zambia 2. Grant number: 16-ZMB-09a-X Date of decision letter: 19 November 2015 3. Date of the partnership framework agreement: 22 October 2014 4. Programme title: New vaccine support (NVS), Measles second dose Routine 5. 6. Vaccine type: Measles 7. Requested product presentation and formulation of vaccine: Measles, 10 doses per vial, LYOPHILISED 8. Programme duration<sup>1</sup>: 2012 - 2016 9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable) 2012-2015 2016 Total<sup>2</sup> Programme US\$ 615,018<sup>3</sup> US\$ 0 US\$ 615,018 budget 10. Vaccine introduction grant: Not applicable **11. Indicative annual amounts:** (subject to the terms of the partnership framework agreement)4 Type of supplies to be purchased 2012-2015 2016 with Gavi funds in each year Annual amounts US\$ 615,0185 US\$ 0 12. Procurement agency: UNICEF 13. Self-procurement: Not applicable 14. Co-financing obligations: Not applicable 15. Operational support for campaigns: Not applicable

<sup>&</sup>lt;sup>1</sup> This is the entire duration of the programme.

<sup>&</sup>lt;sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>&</sup>lt;sup>3</sup> This is the consolidated amount for all previous years.

<sup>&</sup>lt;sup>4</sup> This is the amount that Gavi has approved.

<sup>&</sup>lt;sup>5</sup> This is the consolidated amount for all previously approved years.



**16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

#### 17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,

Hind A. Shalit

**On behalf of Gavi** Hind Khatib-Othman Managing Director, Country Programmes 19 November 2015



## Zambia support for Pentavalent vaccine

This decision letter sets out the programme terms of a programme.

	Date of decision letter: 19 November 2015			
4.	Date of the na	tnershin framewo	ork agreement: 22 O	ctober 2014
		-	<u> </u>	
5.	Programme tit	le: New vaccine st	upport (NVS), Pentava	alent Routine
ô.	Vaccine type:	Pentavalent		
7.	Requested pro		n and formulation of	f vaccine: DTP-Hep
3.	Programme du	iration <sup>6</sup> : 2005 - 20	16	
9.	Programme bu framework agre		(subject to the terms	of the partnership
		2005-2015	2016	Total <sup>7</sup>
	Programme budget	US\$ 54,666,33	5 <sup>8</sup> US\$2,650,500	US\$57,316,835
10.	Vaccine introd	uction grant: Not	applicable	
	Indicative ann	-	applicable ject to the terms of th	ne partnership frame
	Indicative ann agreement) <sup>9</sup>	ual amounts: (sub	ject to the terms of th	
	Indicative annuagreement) <sup>9</sup>	ual amounts: (sub		ne partnership frame
	Indicative annuagreement) <sup>9</sup> Type of supp purchased w	lies to be ith Gavi funds in entavalent	ject to the terms of th	
	Indicative annuagreement) <sup>9</sup> Type of supp purchased w each year Number of P	lies to be ith Gavi funds in entavalent es	ject to the terms of th	2016
	Indicative annu agreement) <sup>9</sup> Type of supp purchased w each year Number of P vaccines dos	lies to be ith Gavi funds in entavalent es D syringes	ject to the terms of th	1,402,400
	Indicative annuation agreement) <sup>9</sup> Type of supp purchased w each year Number of Po vaccines dos Number of A	ual amounts: (sub lies to be ith Gavi funds in entavalent es D syringes afety boxes	ject to the terms of th	2016 1,402,400 1,461,600

<sup>&</sup>lt;sup>6</sup> This is the entire duration of the programme.
<sup>7</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.
<sup>8</sup> This is the consolidated amount for all previous years.

<sup>&</sup>lt;sup>9</sup> This is the amount that Gavi has approved.

<sup>&</sup>lt;sup>10</sup> This is the consolidated amount for all previously approved years.



#### 14. Co-financing obligations: Reference code: 16-ZMB-04a-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased	2016
with Country funds in each year	
Number of vaccine doses	318,800
Number of AD syringes	332,300
Number of safety boxes	3,675
Value of vaccine doses	US\$ 572,887
Total co-financing payments	US\$ 602,500
(including freight)	

15. Operational support for campaigns: Not applicable

**16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May	15 May 2016
each year: number of children to be vaccinated, vaccine	
stock levels including buffer stock, wastage rates, any	
proposed changes in presentation or minimum co-	
financing levels and vaccines received.	
In accordance with applicable Gavi processes, Country	To be agreed
shall report on programmatic and financial performance.	with Secretariat

- 17. Financial clarifications: Not applicable
- 18. Other conditions: Not applicable

Signed by, And H- Schatch

# On behalf of Gavi

Hind Khatib-Othman Managing Director, Country Programmes 19 November 2015



# Zambia support for Pneumococcal vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Zambia 2. Grant number: 16-ZMB-12b-X Date of decision letter: 19 November 2015 3 Date of the partnership framework agreement: 22 October 2014 4. Programme title: New vaccine support (NVS), Pneumococcal Routine 5. Vaccine type: Pneumococcal 6. 7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 doses per vial, LIQUID 8. Programme duration<sup>11</sup>: 2012 - 2016 Programme budget (indicative): (subject to the terms of the partnership 9. framework agreement) Total<sup>12</sup> 2016 2012-2015 Programme US\$ 26,244,940<sup>13</sup> US\$ 6,091,000 US\$ 32,335,940 budget 10. Vaccine introduction grant: Not applicable 11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable)14 Type of supplies to be purchased 2012-2015 2016 with Gavi funds in each year Number of Pneumococcal 1.242.800 vaccines doses Number of AD syringes 1,276,600 Number of safety boxes 14,050 Annual amounts US\$ 26,244,940<sup>15</sup> US\$ 6,091,000 12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF. 13. Self-procurement: Not applicable

<sup>&</sup>lt;sup>11</sup> This is the entire duration of the programme.

<sup>&</sup>lt;sup>12</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>&</sup>lt;sup>13</sup> This is the consolidated amount for all previous years.

<sup>&</sup>lt;sup>14</sup> This is the amount that Gavi has approved.

<sup>&</sup>lt;sup>15</sup> This is the consolidated amount for all previously approved years.



### 14. Co-financing obligations: Reference code: 16-ZMB-12b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased	2016
with Country funds in each year	
Number of vaccine doses	140,400
Number of AD syringes	143,900
Number of safety boxes	1,600
Value of vaccine doses (US\$)	US\$ 472,539
Total co-financing payments	US\$ 484,500
(including freight)	

15. Operational support for campaigns: Not applicable

**16. Additional reporting requirements:** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines,	15 May 2016
Country shall submit the following information in May	
each year: number of children to be vaccinated,	
vaccine stock levels including buffer stock, wastage	
rates, any proposed changes in presentation or	
minimum co-financing levels and vaccines received.	
In accordance with applicable Gavi processes,	To be agreed
Country shall report on programmatic and financial	with Secretariat
performance.	
inancial elevificationes Not applicable	
inancial clarifications: Not applicable	
Other conditions: Not applicable	

Signed by,

Find A. Knath

**On behalf of Gavi** Hind Khatib-Othman Managing Director, Country Programmes 19 November 2015



# Zambia support for **Rotavirus vaccine**

This decision letter sets out the programme terms of a programme.

1.	Country: Zambia	1			
2.	Grant number: 1	6-ZMB-13b-X			
3.	Date of decision	letter: 19 Novembe	er 2015		
4.	Date of the parts	nership framework	agreement: 22 O	ctober 2014	
5.	Programme title	: New vaccine supp	ort (NVS), Rotavir	us Routine	
6.	Vaccine type: R	otavirus			
7.	Requested prod	uct presentation a	nd formulation of	vaccine: Rotavirus	s, 2 dose
8.	Programme dura	ation <sup>16</sup> : 2013 - 2016	6		
9.	Programme bud framework agree	<b>get (indicative):</b> (si ment)	ubject to the terms	of the partnership	
		2013-2015	2016	Total <sup>17</sup>	
	Programme budget	US\$ 7,571,997 <sup>18</sup>	US\$ 1,892,500	US\$ 9,464,497	
10.	Vaccine introdu	ction grant: Not ap	plicable		
11.	Indicative annua agreement) <sup>19</sup>	al amounts: (subjec	t to the terms of th	e partnership frame	ework
	Type of supplies with Gavi funds i	to be purchased n each year	2013-201	15 201	6
	Number of Rotav	virus vaccines doses	3	837,00	0
	Annual amounts		US\$ 7,571,997	<sup>220</sup> US\$ 1,892,50	0
12.	<b>Procurement ag</b> payments each y	ency: UNICEF. The	e Country shall rele	ease its co-financing	g
13.	Self-procureme	nt: Not applicable			

 <sup>&</sup>lt;sup>16</sup> This is the entire duration of the programme.
 <sup>17</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>&</sup>lt;sup>18</sup> This is the consolidated amount for all previous years.

<sup>&</sup>lt;sup>19</sup> This is the amount that Gavi has approved.

<sup>&</sup>lt;sup>20</sup> This is the consolidated amount for all previously approved years.



### 14. Co-financing obligations: Reference code: 16-ZMB-13b-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payments and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased	2016
with Country funds in each year	
Number of vaccine doses	129,000
Value of vaccine doses	US\$282,182
Total co-financing payments	US\$290,000
(including freight)	

#### 15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines,	15 May 2016
Country shall submit the following information in May	
each year: number of children to be vaccinated,	
vaccine stock levels including buffer stock, wastage	
rates, any proposed changes in presentation or	
minimum co-financing levels and vaccines received.	
In accordance with applicable Gavi processes,	To be agreed
Country shall report on programmatic and financial	with Secretariat
performance.	
	•
inancial clarifications: Not applicable	

Signed by, Find A. Shall

On behalf of Gavi Hind Khatib-Othman Managing Director, Country Programmes 19 November 2015

www.gavi.org info@gavi.org